Monitoring of TARC and MDC in blood as tool to evaluate disease activity in patients with Hodgkin Disease
Completed
- Conditions
- lymphnode cancerMorbus Hodgkin10025319
- Registration Number
- NL-OMON30450
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
Children with Morbus Hodgkin (0-18 yrs) included in SKION protocol COG AHOD0031 (METc2004/019)
Exclusion Criteria
Pediatric patients not treated on a COG Hodgkins'Disease protocol
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>* Including children with Morbus Hodgkin in the Netherlands in this study will<br /><br>give a larger power to this study and does mean sooner sufficient patient<br /><br>accrual to achieve a reliable result concerning the value of TARC monitoring to<br /><br>determine the disease activity.<br /><br>* In adult patients is has been proved that the TARC level after treatment<br /><br>has a prognostic value. By including children with Morbus Hodgkin we'll be able<br /><br>to determine if this is also the case with children.<br /><br>* By collecting blood during treatment we possibly can get a good idea about<br /><br>the disease activity and efficiency of the treatment.</p><br>
- Secondary Outcome Measures
Name Time Method <p>If the sensivity of increased TARC and MDC serum levels is hight and patients<br /><br>with consistent low TARC and MDC levels are free from failure, measurement of<br /><br>TARC and MDC could replace expensive CT and PET scans.</p><br>